Michael Luggen, MD
Rheumatology · Cincinnati, OHNPI 1386635431
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,030 of the $13,279 with a category attached, or 90.6%. Sun Pharmaceutical Industries Inc. accounts for 68.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $8,130 and has fallen 88.9% since, to $900 in 2021.
Across 12 payments — averaging $1106.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$9K
- Amgen$4K
Across 305 payments — averaging $3650.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$378K
- Eli Lilly$342K
- Novartis$138K
- GSK$91K
- Sun Pharmaceutical Industries Inc.$71K
- Pfizer$67K
- plus $26K from 4 others
What the payments were for
- Consulting fees$12,03091%
- Travel & lodging$1,0998%
- Food & beverage$1501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 4 | $9,030 |
| Amgen | 8 | $4,249 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILUMYA$8,130
How this compares
$13,279 in reported general payments places this provider in the 80th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 125 | $991,589 |
| Humira(Cf) PenAdalimumab | 47 | $337,841 |
| Humira(Cf)Adalimumab | 22 | $217,889 |
| KevzaraSarilumab | 52 | $216,353 |
| RinvoqUpadacitinib | 26 | $188,050 |
| HumiraAdalimumab | 13 | $169,189 |
| Orencia ClickjectAbatacept | 27 | $152,444 |
| SimponiGolimumab | 24 | $139,958 |
| ActemraTocilizumab | 21 | $96,065 |
| XeljanzTofacitinib Citrate | 14 | $76,487 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $61,901 |
| Hydroxychloroquine Sulfate | 396 | $15,287 |
| Leflunomide | 173 | $9,908 |
| MethotrexateMethotrexate Sodium | 377 | $9,527 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 167 | $7,771 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Cincinnati
- Gregory DelorenzoCincinnati$1.3M
- Robert HiltzCincinnati$165K
- David GreenblattCincinnati$56K
- Emily BowersCincinnati$10K
- John HarleyCincinnati$9K
- Leonard CalabreseCleveland$1.9M
- Alexa MearaColumbus$426K
- Chad DealCleveland$375K
- David MandelMayfield Village$352K
- Muhammad KhanCleveland$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.